Gastrointestinal Stents Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031

The Global Gastrointestinal Stents Market is projected to expand from USD 557.19 Million in 2025 to USD 771.78 Million by 2031, reflecting a compound annual growth rate of 5.58%. These expandable tubular devices, generally constructed from metal or plastic, are engineered to re-establish luminal patency in blocked sections of the digestive tract, such as the biliary tree, colon, and esophagus. Market growth is principally driven by the increasing global prevalence of gastrointestinal malignancies and a growing elderly population that is inherently more prone to digestive blockages. Additionally, the clinical transition toward minimally invasive endoscopic procedures, which provide faster recovery times compared to conventional surgery, acts as a key catalyst for product demand.

Despite these drivers, the market faces significant hurdles due to post-procedural complications like tumor ingrowth, stent migration, and occlusion, which can hinder broader adoption. The critical need for effective obstruction management is underscored by the heavy burden of associated diseases; for instance, the American Cancer Society estimated that 154,270 new cases of colorectal cancer would be diagnosed in the United States in 2025. This substantial volume of diagnoses highlights the urgent necessity for reliable stenting solutions to manage obstructions effectively and enhance the quality of life for patients.

Market Drivers

The primary factor accelerating the Global Gastrointestinal Stents Market is the rising incidence of gastrointestinal cancers, specifically esophageal and biliary malignancies, which require palliative stenting to restore luminal patency. As the global burden of digestive cancers grows, there is an intensified clinical need for effective tools to manage symptoms like dysphagia and blockages in patients with inoperable tumors. According to the 'Cancer Facts & Figures 2025' report released by the American Cancer Society in January 2025, approximately 22,070 new cases of esophageal cancer were projected to be diagnosed in the United States alone, a figure that directly increases the demand for durable stenting solutions as a vital part of supportive oncology care.

Simultaneously, the market is being propelled by a growing preference for minimally invasive endoscopic techniques as healthcare providers move away from traditional open surgeries. This shift is supported by the development of advanced stent designs that allow for more precise placement and fewer complications, thereby encouraging higher procedure volumes. The economic strength of this sector is reflected in the performance of major industry players; for example, Boston Scientific reported a 12.4% increase in net sales for its MedSurg segment, which includes its endoscopy portfolio, in its 'Fourth Quarter and Full Year 2024 Financial Results' in February 2025. Furthermore, Olympus recorded an adjusted operating profit of ¥188.5 billion in its 2025 fiscal year results, demonstrating the significant economic value generated by these medical technologies.

Market Challenges

A critical obstacle impeding market growth involves the post-procedural complications associated with gastrointestinal stents, particularly stent migration, tumor ingrowth, and occlusion. These adverse events frequently require repeat interventions, which increase the physical strain on patients and add financial costs to healthcare systems. When stents fail to maintain luminal patency due to displacement or tissue overgrowth, the perceived reliability of these devices diminishes, leading healthcare providers to exercise caution in recommending stenting for obstruction management, which potentially limits procedural volumes and slows overall clinical adoption.

The impact of these complications is exacerbated by the high prevalence of conditions requiring biliary drainage, where device failure can be especially detrimental. According to the American Society of Clinical Oncology, an estimated 66,440 adults in the United States were diagnosed with pancreatic cancer in 2024. Since pancreatic malignancies often cause biliary obstructions that necessitate stenting, the persistent risk of occlusion or migration within such a large patient population creates a significant barrier to market confidence, with the frequency of these adverse events continuing to restrain the aggressive expansion of the gastrointestinal stents market.

Market Trends

The emergence of Lumen-Apposing Metal Stents (LAMS) is revolutionizing the management of biliary obstructions and pancreatic fluid collections by enabling therapeutic drainage without the need for traditional surgery. These specialized dumbbell-shaped devices establish a stable, temporary conduit between the gastrointestinal tract and adjacent cavities, significantly simplifying procedures for conditions such as walled-off necrosis. This shift toward interventional solutions is evidenced by the commercial success of leading device platforms; in February 2025, Boston Scientific reported in its 'Fourth Quarter and Full Year 2024 Financial Results' that its endoluminal surgery franchise achieved double-digit growth, a performance attributed to the sustained adoption of the AXIOS stent platform and its expanded regulatory approval for gallbladder drainage in Japan.

In parallel, the adoption of bioresorbable and biodegradable stents is increasing as a solution to eliminate the need for secondary removal procedures and reduce long-term device-related complications. These advanced stents are engineered to maintain luminal patency for a specific period before gradually dissolving, thereby mitigating risks such as tissue ingrowth and stent migration that are frequently associated with permanent plastic or metal alternatives. The clinical validation of these devices is accelerating their integration into standard practice; for instance, a 2025 article in Frontline Gastroenterology titled 'Use of biodegradable stents in ERCP: lessons from a single high-volume centre' detailed a retrospective study of 132 patients that demonstrated the effectiveness of these dissolving stents for complex biliary and pancreatic indications, confirming their utility in lowering the burden of repeat interventions.

Key Players Profiled in the Gastrointestinal Stents Market

• Boston Scientific Corporation
• Cook Group Inc.
• Becton Dickinson & Co Ltd.
• CONMED Corporation
• Cantel Medical LLC
• ELLA-CS, s.r.o.
• Hobbs Medical Inc.
• Merit Medical Systems, Inc.
• Olympus Corp.
• Diagmed Healthcare Ltd.

Report Scope

In this report, the Global Gastrointestinal Stents Market has been segmented into the following categories:

Gastrointestinal Stents Market, by Product Type:

• Biliary Stent
• Colonic Stent
• Duodenal Stent
• Esophageal Stent
• Pancreatic Stent

Gastrointestinal Stents Market, by Application:

• Biliary Disease
• Colorectal Cancer
• Stomach Cancer
• Inflammatory Bowel Disease
• Others

Gastrointestinal Stents Market, by Region:

• North America
• Europe
• Asia-Pacific
• South America
• Middle East & Africa

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Gastrointestinal Stents Market.

Available Customization

The analyst offers customization according to your specific needs. The following customization options are available for the report:

• Detailed analysis and profiling of additional market players (up to five).

This product will be delivered within 1-3 business days.